Elucidating the role of API in the PI3K/AKT/p53 pathway provides a scientific foundation for future preclinical and clinical investigations intended to harness this natural compound for the targeted elimination of BCSCs and to improve patient outcomes in breast cancer treatment. This evidence concerns the gene TP53 and breast carcinoma.